Skip to content

Formulation, Process Optimization, and in Vitro–in Vivo Evaluation of Buccal Effervescent Tablets of BCS Class II and Class IV Drugs: Asenapine Maleate and Telmisartan Cilexetil

Sep 2026 · Natural Resources for Human Health · Vol 6, pp. 405-423 · 0 citations · 25 references

TL;DR

Optimized formulations were evaluated for in vitro dissolution, in vitro buccal permeation through freshly excised goat mucosa using Franz diffusion cells, buccal mucosal irritation (histopathology), in vivo pharmacokinetics in New Zealand White rabbits, and 12-month ICH accelerated stability.

Abstract

Conventional oral drug delivery is inadequate for drugs with extensive first-pass hepatic metabolism or poor gastrointestinal solubility and permeability. This study aimed to design, formulate, and comprehensively evaluate BETs of asenapine maleate (ASM; BCS Class II) and telmisartan cilexetil (TC; BCS Class IV) as candidate drugs for which oral bioavailability is critically limited. Preformulation studies (pH-dependent solubility, physicochemical characterization, FTIR and DSC drug-excipient compatibility) were performed for both drugs. Placebo effervescent granules were manufactured by RMG and FBP and characterized by SEM, particle size, compressibility, and flow. A 3 3 full factorial DoE (Design Expert® v9.0.4) with sodium bicarbonate (X₁), citric acid anhydrous (X₂), and tartaric acid (X₃) as factors optimized for disintegration time (R₁) and microenvironmental pH (R₂). Optimized formulations were evaluated for in vitro dissolution, in vitro buccal permeation through freshly excised goat mucosa using Franz diffusion cells, buccal mucosal irritation (histopathology), in vivo pharmacokinetics in New Zealand White rabbits, and 12-month ICH accelerated stability. FBP produced spherical, uniform granules (447–516 μm; Carr's index 12.10±0.32%; moisture 0.13%) superior to RMG in all quality attributes. The optimized ASM-BET (Batch F17; pH 4.5±0.2; DT 5.14±0.12 min) released 91.38±4.6% drug at 14 min, versus 68.12±4.9% for the marketed comparator (ASENAPT-5®), representing a 34% improvement. Permeation flux was 2.18-fold greater than the reference. The optimized TC-BET (Batch F2; pH 6.86; DT 6.7±2.3 min) demonstrated similarly enhanced dissolution and permeation. Buccal mucosal histopathology confirmed absence of irritation. In vivo pharmacokinetic studies in rabbits showed relative bioavailability of 147.2% (ASM-BET) and 142.8% (TC-BET) versus respective reference formulations, with significantly elevated AUC and Cₘₐₓ.

View source

Similar papers

Oct 2026

Formulation and Optimization of Cilnidipine Nanoparticle-loaded Mucoadhesive Buccal Tablets using Quality by Design Approach for Enhanced Systemic Bioavailability

Cilnidipine, a calcium channel blocker used to treat hypertension, has poor oral bioavailability owing to extensive first-pass intestinal and hepatic metabolism. Buccal delivery offers an alternative route that bypasses hepatic first-pass metabolism and provides controlled systemic absorption. This study aimed to f...

Mahallingan K, Vedamurthy Joshi · 0 citations
Open access Oct 2026

Formulation and characterization of solid dispersion adsorbate of Candesartan Cilexetil: in vitro dissolution and in vivo performance

Candesartan Cilexetil (CC) is a non-peptide angiotensin II type 1 receptor antagonist widely used in the treatment of hypertension. However, CC has poor aqueous solubility (0.006 ± 0.002 mg/mL), low oral bioavailability (15%) and undergoes significant first-pass metabolism. Candesartan Cilexetil Solid Disp...

Harshad Makwana, Anjali Patel, M. Lalan et al. · 0 citations
Review Open access Sep 2026

Solubility Enhancement Strategies for BCS Class II Drugs in Orally Disintegrating Tablet Platforms: A Review

Objective(s): To critically review and synthesize solubility enhancement strategies applied to Biopharmaceutics Classification System (BCS) Class II drugs formulated as orally disintegrating tablets (ODTs), with particular attention to how dissolution-rate-limiting solubility constraints are addressed without compromis...

Swarnalatha Sangalapalle · 0 citations
Open access Sep 2026

Amlodipine besylate and valsartan combined mucoadhesive buccal patch formulations: In-vitro release and ex-vivo permeation studies.

BACKGROUND Oral fixed-dose combinations of Amlodipine Besylate and Valsartan are widely prescribed for hypertension but are associated with first-pass metabolism and variable bioavailability. Buccal drug delivery provides a favorable substitute to improve systemic availability and provide sustained release. OBJECTIVE...

N. Anwar, Rahman Gul, S. U. Jan et al. · 0 citations
Oct 2026

Optimization, In vitro and In vivo Evaluation of an Azithromycin Nanosuspension-Based Nanogel for Enhanced Dermal Delivery.

INTRODUCTION/OBJECTIVE Azithromycin is a BCS class II macrolide antibiotic characterized by poor aqueous solubility, a limited dissolution rate, and relatively low oral bioavailability (37%), limiting its therapeutic effectiveness for the treatment of skin infections. This study aimed to design and optimize an azithrom...

O. S. Salih, N. Toma, Manar Adnan Tamer et al. · 0 citations
Open access Nov 2026

STUDY ON FORMULATION, CHARACTERIZATION AND MODIFICATION OF SUSTAINED RELEASE BILAYER MATRIX TABLETS OF PROPRANOLOL HCl AND NIFEDIPINE FOR ANTIHYPERTENSIVE THERAPY

Background: Sustained-release (SR) bilayer matrix tablets allow two release segments, or two drugs, to be combined in one dosage unit. Propranolol hydrochloride (BCS class I) and nifedipine (BCS class II) are complementary antihypertensives, but their contrasting solubility makes the design of a shared SR system challe...

Sheeba Naaz, H. Bhardwaj · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.